(NASDAQ: IRWD) IRONWOOD PHARMACEUTICALS's forecast annual revenue growth rate of 5.16% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.93%.
IRONWOOD PHARMACEUTICALS's revenue in 2022 is $422,437,000.On average, 2 Wall Street analysts forecast IRWD's revenue for 2022 to be $66,004,136,407, with the lowest IRWD revenue forecast at $65,904,141,794, and the highest IRWD revenue forecast at $66,104,131,020. On average, 2 Wall Street analysts forecast IRWD's revenue for 2023 to be $70,784,648,093, with the lowest IRWD revenue forecast at $70,503,893,988, and the highest IRWD revenue forecast at $71,065,402,199.
In 2024, IRWD is forecast to generate $75,569,774,915 in revenue, with the lowest revenue forecast at $75,442,089,486 and the highest revenue forecast at $75,697,460,344.